Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.44 |
| ▸ | INSR | P06213 | 5/20 | 0.44 |
| ▸ | IGF1R | P08069 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26379932 | 0.96 | EGFR (0.56) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26379893 | 0.94 | EGFR (0.54) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26379916 | 0.93 | EGFR (0.52) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26379773 | 0.93 | EGFR (0.53) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26379435 | 0.92 | EGFR (0.52) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26378906 | 0.92 | EGFR (0.57) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26378843 | 0.92 | EGFR (0.62) | EGFRMET | |
| SCHEMBL25789270 | 0.92 | EGFR (0.52) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26379745 | 0.92 | EGFR (0.52) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26403955 | 0.91 | EGFR (0.55) | EGFRALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885MET 9/4885ALK 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.